Free Trial
NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$47.03 +0.05 (+0.11%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$47.02 -0.01 (-0.01%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Advanced

Key Stats

Today's Range
$46.10
▼
$47.44
50-Day Range
$39.08
▼
$47.89
52-Week Range
$27.00
▼
$55.67
Volume
1.43 million shs
Average Volume
1.83 million shs
Market Capitalization
$7.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.73
Consensus Rating
Moderate Buy

Company Overview

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts.

Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

Alkermes also conducts research and development in neuroscience, seeking to advance treatments for psychiatric and addiction-related disorders. Its commercial activities are centered primarily on the U.S. market.

AI Generated. May Contain Errors.

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

ALKS MarketRank™: 
2.557788284735 of 5 stars

Alkermes scored higher than 51% of companies evaluated by MarketBeat, and ranked 527th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 10 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Alkermes has a consensus price target of $55.73, representing about 18.5% upside from its current price of $47.03.

  • Amount of Analyst Coverage

    Alkermes has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow in the coming year, from ($0.52) to $0.36 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is -2,350.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is -2,350.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.25% of the float of Alkermes has been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 11.25, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 3.15%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • News Sentiment

    Alkermes has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Alkermes this week, compared to 6 articles on an average week.
  • Search Interest

    4 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070,940.00 in company stock.

  • Percentage Held by Insiders

    4.59% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALKS Stock News Headlines

Alkermes Stock Earnings Estimates Lifted by HC Wainwright
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $27.98 at the beginning of the year. Since then, ALKS shares have increased by 68.1% and is now trading at $47.03.

Alkermes plc (NASDAQ:ALKS) released its earnings results on Wednesday, November, 4th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.17. The firm's revenue for the quarter was up 21.8% compared to the same quarter last year.
Read the conference call transcript
.

Alkermes subsidiaries include Rodin Therapeutics.

Top institutional investors of Alkermes include State Street Corp (6.03%), First Trust Advisors LP (1.18%), Public Sector Pension Investment Board (0.64%) and GW&K Investment Management LLC (0.63%). Insiders that own company stock include David Joseph Gaffin, Shane Cooke, Christian Todd Nichols, Craig C Hopkinson, Christopher I Wright, Cato T Laurencin and Nancy Lynn Md Snyderman.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Gilead Sciences (GILD) and Intel (INTC).

Company Calendar

Last Earnings
11/04/2026
Today
11/15/2026
Jefferies Global Healthcare Conference
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
CIK
1520262
Employees
2,050
Year Founded
1987

Price Target and Rating

High Price Target
$68.00
Low Price Target
$36.00
Potential Upside/Downside
+18.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
130.64
P/E Growth
N/A
Net Income
$241.66 million
Net Margins
-0.02%
Pretax Margin
0.65%
Return on Equity
0.40%
Return on Assets
0.19%

Debt

Debt-to-Equity Ratio
0.79
Current Ratio
2.42
Quick Ratio
2.02

Sales & Book Value

Annual Sales
$1.48 billion
Price / Sales
5.35
Cash Flow
$1.68 per share
Price / Cash Flow
28.06
Book Value
$11.10 per share
Price / Book
4.24

Miscellaneous

Outstanding Shares
168,040,000
Free Float
160,331,000
Market Cap
$7.90 billion
Optionable
Optionable
Beta
0.32

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners